Colon and Rectal Cancer Drugs Market Continues to Grow as Bristol-Myers Squibb Partners with Bayer AG to test Opdivo and Stivarga in patients with microsatellite stable metastatic colorectal cancer

Colorectal Cancer is the medical name for cancer that occurs in the rectum or colon, which in combination with its numerous other names makes up the large intestines. Colon cancer, among the most prevalent cancers in America, accounts for more than half of all cancers diagnosed in the U.S. As a result, the treatment and outcomes of this debilitating disease can greatly affect your quality of living. The difficulty of detecting colorectal cancer contributes greatly to the difficulty of treating it. For this reason, many doctors will try to remove any polyps and tumor that they are able to discover through surgical techniques only to find that the cancer had re-appeared later at an even more advanced stage.

Increasing incidence of colorectal cancer is expected to drive growth of the global colon and rectal cancer drugs market. According to the American Society of Clinical Oncology (ASCO), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S. According to the same source, around 147,950 adults in the U.S. were diagnosed with colorectal cancer, of which 104,610 new cases of colon cancer and 43,340 new cases of rectal cancer. As a result of this, the demand for adequate medications, therapeutics, and treatment options has increased significantly in the recent past. Hence, such factors are expected to drive growth of the global colon and rectal cancer drugs market. Furthermore, proactive government initiatives to provide better and affordable treatments are expected to propel the global colon and rectal cancer drugs market growth in the near future. For instance, in December 2020, Stand Up To Cancer received a US$ 10 million grant from Exact Sciences to enhance colorectal cancer screening and prevention.  

However, adverse effects associated with cancer drugs and high cost of these drugs are expected to restrain growth of the global colon and rectal cancer drugs market. Among regions, North America is expected to witness significant growth in the global colon and rectal cancer drugs market. This is owing to high incidence of colorectal cancer and increasing adoption of novel treatment options. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to high unmet clinical needs and rising disposable income in the region.

Key companies involved in the global colon and rectal cancer drugs market are Eli Lilly and Company, Amgen, Sanofi, Bayer, Roche, Bristol-Myers Squibb, and Merck.

For instance, in July 2019, Bristol-Myers Squibb partnered with Bayer AG, a German pharmaceutical and life sciences company, to test Opdivo and Stivarga in patients with microsatellite stable metastatic colorectal cancer